VIVOS INC (RDGL) Form 10-Q — May 14, 2026
Vivos Inc reported a net loss of $1.18 million for the three months ended March 31, 2026, with revenue of $36,068 derived primarily from its veterinary IsoPet therapy division. The company ended the quarter with $2.53 million in cash, which management explicitly stated is insufficient to cover fixed and variable obligations, raising significant doubt about its ability to continue as a going concern. The filing discloses a material weakness in internal controls related to the proper segregation of duties, noting that disclosure controls were ineffective.
Key figures
- Revenue
- 36068
- Total Debt
- 0
- Revenue Yoy
- 34.8%
- Cash Position
- 2525782
- Shares Outstanding
- 482840608
- Working Capital
- 2427649
- Rsus Outstanding
- 56150000
- Options Outstanding
- 2252809
- Warrants Outstanding
- 25165000
- Annual Funding Requirement
- 3000000
- Three Year Capital Requirement
- 9000000
Price after filing
Close on the filing date to close N calendar days later (from $0.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.